Primary and secondary outcome data
| . | PCNSL . | SCNSL . |
|---|---|---|
| Patients (n) | 30 | 98 |
| CRS; % (95% CI) | ||
| All grade | 70 (51.0, 84.0) | 72 (58.0, 83.0) |
| Grade 3 + 4 | 13 (5.0, 32.0) | 11 (6.0, 19.0) |
| Immune effector cell-associated neurotoxicity syndrome (ICANS); % (95% CI) | ||
| All grade | 53 (34.0, 71.0) | 48 (35.0, 60.0) |
| Grade 3 + 4 | 18 (8.0, 37.0) | 26 (18.0, 37.0) |
| Median follow-up (months) | 12.2 | 10.1 |
| Efficacy, % (95% CI) | ||
| CR | 56 (38.0, 73.0) | 47 (36.0, 59.0) |
| CR at 28 d | 31 (16.0, 52.0) | 32 (18.0, 51.0) |
| CR at 90 d | 40 (22.0, 61.0) | 37 (27.0, 50.0) |
| CR at 180 d | 37 (22.0, 55.0) | 37 (26.0, 50.0) |
| Partial remission | 12 (4.0, 30.0) | 24 (14.0, 39.0) |
| ORR, % (95% CI) | 64 (46.0, 79.0) | 57 (46.0, 67.0) |
| Ongoing responses at data cutoff, % (95% CI) | 37 (20.0, 57.0) | 46 (32.0, 60.0) |
| Median duration of response (mo) | 8.97 (5.82-9.34) | 4.63 (2.86-16.03) |
| . | PCNSL . | SCNSL . |
|---|---|---|
| Patients (n) | 30 | 98 |
| CRS; % (95% CI) | ||
| All grade | 70 (51.0, 84.0) | 72 (58.0, 83.0) |
| Grade 3 + 4 | 13 (5.0, 32.0) | 11 (6.0, 19.0) |
| Immune effector cell-associated neurotoxicity syndrome (ICANS); % (95% CI) | ||
| All grade | 53 (34.0, 71.0) | 48 (35.0, 60.0) |
| Grade 3 + 4 | 18 (8.0, 37.0) | 26 (18.0, 37.0) |
| Median follow-up (months) | 12.2 | 10.1 |
| Efficacy, % (95% CI) | ||
| CR | 56 (38.0, 73.0) | 47 (36.0, 59.0) |
| CR at 28 d | 31 (16.0, 52.0) | 32 (18.0, 51.0) |
| CR at 90 d | 40 (22.0, 61.0) | 37 (27.0, 50.0) |
| CR at 180 d | 37 (22.0, 55.0) | 37 (26.0, 50.0) |
| Partial remission | 12 (4.0, 30.0) | 24 (14.0, 39.0) |
| ORR, % (95% CI) | 64 (46.0, 79.0) | 57 (46.0, 67.0) |
| Ongoing responses at data cutoff, % (95% CI) | 37 (20.0, 57.0) | 46 (32.0, 60.0) |
| Median duration of response (mo) | 8.97 (5.82-9.34) | 4.63 (2.86-16.03) |